Page 54 - Read Online

Hall et al. Hepatoma Res. 2026;12:20 Page 15 of 15

49. Malone CD, Bajaj S, He A, et al. Combining radioembolization and immune checkpoint inhibitors for the treatment of hepatocellular
carcinoma: the quest for synergy. J Vasc Interv Radiol. 2025;36:414-424.e2. DOI
50. Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 2018;29:iv238-55. DOI
51. Riaz A, Ryu RK, Kulik LM, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker
of radiologic response, progression, and survival. J Clin Oncol. 2009;27:5734-42. DOI
52. Llovet JM, Di Bisceglie AM, Bruix J, et al. ; for the panel of experts in HCC-Design Clinical Trials. Design and endpoints of clinical
trials in hepatocellular carcinoma. JNCI: J Nat Cancer I. 2008;100:698-711. DOI
53. Dakal TC, George N, Xu C, Suravajhala P, Kumar A. Predictive and prognostic relevance of tumor-infiltrating immune cells: tailoring
personalized treatments against different cancer types. Cancers. 2024;16:1626. DOI PubMed PMC

Disclaimer/Publisher’s Note: All statements, opinions, and data contained in this publication are solely those of the individual author(s) and
contributor(s) and do not necessarily reflect those of OAE and/or the editor(s). OAE and/or the editor(s) disclaim any responsibility for harm to
persons or property resulting from the use of any ideas, methods, instructions, or products mentioned in the content.

© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License
(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and
reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and
the source, provide a link to the Creative Commons license, and indicate if changes were made.